The revival of a potential drug to fight Alzheimer’s, whose clinical trials had been declared futile just months ago, proved the value of sticking with the search for treatments for the disease when other pharmaceuticals companies are “running away”, according to the chief executive of its developer, Biogen. By announcing on Tuesday that it would seek regulatory approval after all for its drug aducanumab, the US biotech company gave new hope to millions of patients and caregivers — and its shareholders. Read the complete article here (PDF).
- ProMIS Neurosciences Announces Results of Annual Meeting of Shareholders July 29, 2020
- ProMIS Neurosciences and BC Neuroimmunology announce revenue-sharing joint venture agreement to develop and offer blood-based diagnostic tests for Alzheimer’s disease July 9, 2020
- ProMIS Neurosciences announces adjournment and change of location of annual meeting of shareholders June 24, 2020